GlassScriptPhysician profile
Michael R Bonsaver
NPI 1336552132
$1,482.81
in general payments reported to CMS, 2019-2025
22 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $324 · 2023: $650 · 2024: $75.05 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.84 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $245.83 | 2022-2025 | |
| Abbvie INC. | $169.21 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.40 | 2021-2022 | |
| Genzyme Corporation | $121.75 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $120.53 | 2022-2023 | |
| Seagen INC. | $108.55 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Aveo Pharmaceuticals, INC. | $90.46 | 2023 | Fotivda |
| Dova Pharmaceuticals | $80.28 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $41.80 | 2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $37.91 | 2022 | |
| Stemline Therapeutics INC. | $28.72 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $26.83 | 2023 | Keytruda |
| Daiichi Sankyo INC. | $25.71 | 2023 | Enhertu |
| Astellas Pharma US INC | $23.50 | 2023 | Padcev |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2023 | |
| Puma Biotechnology, INC. | $19.28 | 2023 | |
| Array Biopharma INC | $18.96 | 2023 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $17.92 | 2023 | Trodelvy |
| Progenics Pharmaceuticals, INC. | $17.39 | 2023 | Pylarify |
| Janssen Biotech, INC. | $15.91 | 2023 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bonsaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.